Baird Medical Secures $3.7M in Highly Dilutive Convertible Note Financing
BDMD sits 15% above its 52-week low of $0.661 on light trading volume (0.4× avg).
Summary
Baird Medical has raised $3.7 million via a highly dilutive convertible note with terms that heavily favor the investor, including a low conversion floor and a security interest in U.S. assets, potentially diluting existing shareholders by over 86%.
Key Events · Financing and Capital Events · BDMD
-
Convertible Note Offering
The company issued a US$4.35 million senior 8% original issue discount convertible promissory note, yielding approximately $3.7 million in net proceeds after expenses.
-
Significant Potential Dilution
The note is convertible into up to 27,517,886 ordinary shares at a floor price of $0.158 per share, plus up to 110,070 commitment shares. This represents a potential dilution of 86.33% to existing shareholders, based on 32,002,370 shares outstanding prior to the offering.
-
Investor-Favorable Terms
The conversion price is the lower of a fixed $0.9842 or 92% of the lowest 7-day VWAP (85% on default), with a floor of $0.158. The note is senior and secured by a pledge of the U.S. operating subsidiary's equity and a lien on substantially all U.S. assets.
-
Critical Capital Raise
This capital raise follows a recent disclosure (July 27, 2026 20-F/A) of a $27.5 million loss and only $0.2 million in cash, highlighting the company's urgent need for capital despite recent positive H1 2026 net income.
Analysis · BDMD · Industrial Applications And Services
Baird Medical, a company that recently reported very low cash reserves, has secured $3.7 million in net proceeds through a senior 8% original issue discount convertible promissory note. While the fixed conversion price is above the recent market price, the note includes an alternative conversion price and a very low floor price of $0.158 per share, which could lead to substantial dilution for existing shareholders if the stock price declines. The offering also includes up to 110,070 additional shares as commission and grants the investor a security interest in the company's U.S. operating subsidiary and substantially all U.S. assets, indicating a high-risk financing structure. This capital raise is critical for the company's liquidity but comes at a significant cost to current equity holders.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDMD was trading at $0.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $32.9M. The 52-week trading range was $0.66 to $3.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.